| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | New Constructs, LLC |
N/A
| ISTA: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ISTA | 13 |
$25 |
| 29-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for ISTA Pharmaceuticals, Inc. | 42 |
$65 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: ISTA PHARMACEUTICALS INC | 5 |
$25 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ISTA PHARMACEUTICALS INC (ISTA=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ISTA PHARMACEUTICALS INC (ISTA=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ISTA PHARMACEUT -- ISTA | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ALXA , ALTH , ARIA , COR , DEPO , ISTA , PTIE , QCOR -- DRUGS | 3 |
$4 |
0.34% Nasdaq 
Research Reports
